Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

Date publication

juin 2012

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr CONROY Thierry , Dr LUPORSI Elisabeth , Pr PEIFFERT Didier

Tous les auteurs :
Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22529257

Résumé

Concomitant radiochemotherapy (RCT) is the standard for locally advanced anal canal carcinoma (LAACC). Questions regarding the role of induction chemotherapy (ICT) and a higher radiation dose in LAACC are pending. Our trial was designed to determine whether dose escalation of the radiation boost or two cycles of ICT before concomitant RCT lead to an improvement in colostomy-free survival (CFS).

Mots clés

Adult, Aged, Anal Canal, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Anus Neoplasms, drug therapy, Chemoradiotherapy, methods, Cisplatin, administration & dosage, Drug Administration Schedule, Female, Humans, Induction Chemotherapy, Male, Middle Aged, Radiotherapy Dosage

Référence

J. Clin. Oncol.. 2012 Jun;30(16):1941-8